PharmaCyte Biotech’s Cancer Treatment Shows “Complete Tumor Remission” in Published Preclinical Study
Written by Ι Stock Market Media — June 3, 2015
NEW YORK, NY — PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate video by the company. In that video, PharmaCyte revealed that its cancer treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide was able to produce “complete tumor remission in all animals” that received the treatment on days 2-6 of a previously published preclinical study.
It was a study ...
Read More →
3
JUN
Share
PharmaCyte Biotech Equity Research by Stonegate Capital Partners
On May 28, 2015, Stonegate Capital Partners released an extensive Equity Research Report on PharmaCyte Biotech, Inc. The firm’s reports are issued to targeted funds, and institutional investors also have access to Stonegate’s research from a variety of services including Bloomberg, Thomson Reuters, Zach’s, Capital IQ, The Markets, Morningstar and FactSet among others. Stonegate has the ability to actively track the institutional investors who access their research.
Click to View Stonegate Capital Partners Equity Research on PharmaCyte ...
Read More →
31
MAY
Share
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
Written by Ι Stock Market Media Group — April 23, 2015
PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce ...
Read More →
23
APR
Share
Nuvilex Announces Name Change to PharmaCyte Biotech
SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...
Read More →
7
JAN
Share
FDA Grants Orphan Drug Designation to Nuvilex, Inc. for Pancreatic Cancer Treatment
SILVER SPRING, Md., Dec. 22, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are ...
Read More →
22
DEC
Share
Nuvilex Begins Preclinical Studies at Translational Drug Development
SILVER SPRING, Md., Aug. 20, 2014 — Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex’s unique cancer treatment can slow the accumulation of fluid, known as “malignant ascites,” in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President ...
Read More →
20
AUG
Share
